Literature DB >> 28428615

Metabolic Disease: Protein tyrosine phosphatase inhibitor reverses diabetes.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28428615     DOI： 10.1038/nrd.2017.73

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase.

Authors:  Stephanie M Stanford; Alexander E Aleshin; Vida Zhang; Robert J Ardecky; Michael P Hedrick; Jiwen Zou; Santhi R Ganji; Matthew R Bliss; Fusayo Yamamoto; Andrey A Bobkov; Janna Kiselar; Yingge Liu; Gregory W Cadwell; Shilpi Khare; Jinghua Yu; Antonio Barquilla; Thomas D Y Chung; Tomas Mustelin; Simon Schenk; Laurie A Bankston; Robert C Liddington; Anthony B Pinkerton; Nunzio Bottini
Journal:  Nat Chem Biol       Date:  2017-03-27       Impact factor: 15.040
  1 in total
  3 in total

Review 1.  Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities.

Authors:  Chiranjeev Sharma; Youllee Kim; Dohee Ahn; Sang J Chung
Journal:  Arch Pharm Res       Date:  2021-02-15       Impact factor: 4.946

2.  PRL-2 phosphatase is required for vascular morphogenesis and angiogenic signaling.

Authors:  Mathilde Poulet; Jacinthe Sirois; Kevin Boyé; Noriko Uetani; Serge Hardy; Thomas Daubon; Alexandre Dubrac; Michel L Tremblay; Andreas Bikfalvi
Journal:  Commun Biol       Date:  2020-10-23

Review 3.  A Comprehensive Review of Receptor-Type Tyrosine-Protein Phosphatase Gamma (PTPRG) Role in Health and Non-Neoplastic Disease.

Authors:  Christian Boni; Carlo Laudanna; Claudio Sorio
Journal:  Biomolecules       Date:  2022-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.